Agile Logo  
   
line decor
 
line decor

 
 
 
 
AG200-15 CLINICAL PROFILE


In Phase 2 clinical studies, AG200-15 exceeded all of its target endpoints.

Agile’s lead program is a low-dose contraceptive patch which will address a significant market need for safe, effective and convenient birth control.
 
 
 

  
 
             
Agile Therapeutics | 366 Wall Street | Princeton, NJ 08540 | (609) 683-1880
Home | About Agile | Our Pipeline | Therapeutic Market | Investors | News and Events | Contact Us
Sitemap | Terms and Conditions | © 2008 Agile Therapeutics